2017
Current biologic therapies (including IL-17) and monitoring guidelines
Strober B, Wald J. Current biologic therapies (including IL-17) and monitoring guidelines. 2017, 233-240. DOI: 10.1201/9781315119298-23.Peer-Reviewed Original ResearchTuberculin skin testLatent tuberculosisBiologic therapyQuantiFERON-TB Gold testPhase 3 clinical trialsCurrent biologic therapiesInitiation of treatmentSeverity Index scoreInterferon-gamma releaseEfficacy of treatmentHuman monoclonal antibodyMembrane-bound TNFPsoriasis AreaAtypical presentationGamma releaseSkin testThorough historyClinical trialsGold testIndex scoreControl populationMonoclonal antibodiesTNFAdverse effectsTuberculosis
2009
A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal Of The American Academy Of Dermatology 2009, 61: s1-s46. PMID: 19527820, DOI: 10.1016/j.jaad.2009.03.017.Peer-Reviewed Original ResearchConceptsTreatment optionsSevere psoriasisAvailable evidence-based dataHistory of malignancyEfficacious treatment optionBreast-feeding womenMedical treatment optionsSystemic psoriasis therapiesEvidence-based dataDelphi consensus approachLatent tuberculosisPsoriatic diseaseLiver diseasePsoriasis therapyHealthy patientsTreatment recommendationsClinical trialsCardiovascular diseaseConsensus panelViral infectionPatientsOptimum managementDisease statesMedical evidenceDisease